Adverse events of Oxford/AstraZeneca's COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia

Tequare, Mengistu Hagazi; Abraha, Hiluf Ebuy; Adhana, Mache Tsadik; Tekle, Tesfay Hailu; Belayneh, Eskedar Kebede; Gebresilassie, Kibrom Berhanu; Wolderufael, Abadi Leul; Ebrahim, Mohamedawel Mohamedniguss; Tadele, Berihun Afera; Berhe, Derbew Fikadu; Ashebir, Mengistu Mitiku; Gebrehiwot, Kibrom Gebresilasie; Atsbaha, Merhawit; Berihu, Birhane Alem; Desta, Kibrom Gebresilasie; Atsbaha, Mussie Tesfay; Mengesha, Reiye Esayas; Tsegay, Mehari Abraha; Sibhatu, Manuel Kassaye

doi:10.1016/j.ijregi.2021.10.013

Cited by 19 publications

(43 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further, our study found that physicians aged 61-70 years were almost 96% less likely to have adverse events than physicians in their twenties. Similar age-related findings were reported in other studies of Covisheild, 32,36 Pfizer-BioNTech and Moderna vaccine recipients. 40 Reactogenicity is usually induced by innate and adaptive immune responses leading to the release of chemokine and cytokines.…”

Section: Discussionsupporting

confidence: 90%

“…Further, our study found that physicians aged 61–70 years were almost 96% less likely to have adverse events than physicians in their twenties. Similar age‐related findings were reported in other studies of Covisheild, 32 , 36 Pfizer‐BioNTech and Moderna vaccine recipients. 40 …”

Section: Discussionsupporting

confidence: 89%

“…One‐quarter of respondents in a general‐population Bangladeshi study used acetaminophen to minimize vaccine‐associated discomfort, 25 as did 33.3% of HCPs in an Ethiopian study. 36 …”

Section: Discussionmentioning

confidence: 99%

“…An Ethiopian study of HCPs also found that the presence of comorbidities doubled the risk of reactogenicity. 36 Despite an increased risk of adverse vaccine reactions, people with underlying medical conditions are also at increased risk of COVID‐19 infections. 52 The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization clinical trials with the Oxford‐AstraZeneca (Covishield) vaccine (AZD1222) concluded that people with comorbidities (obesity, cardiovascular disease, respiratory disease and diabetes) had an increased risk of severe COVID‐19.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians

et al. 2022

View full text Add to dashboard Cite

Increased COVID‐19 vaccine hesitancy presents a major hurdle in global efforts to contain the COVID‐19 pandemic. This study was designed to estimate the prevalence of adverse events after the first dose of the Covishield (AstraZeneca) vaccine among physicians in Bangladesh. A cross‐sectional study was conducted using an online questionnaire for physicians ( n = 916) in Bangladesh. Physicians who received at least one dose of the COVID‐19 vaccine were included. The study was carried out from April 12 to May 31, 2021. More than 58% of respondents ( n = 533) reported one or more adverse events. Soreness of the injected arm (71.9%), tiredness (56.1%), fever (54.4%), soreness of muscles (48.4%), headache (41.5%) and sleeping more than usual (26.8%) were the most commonly reported adverse events. Most vaccine‐related reactogenicities were reported by the younger cohorts (<45 years). The majority of respondents reported severity of reactogenicity as “mild,” experienced on the day of vaccination, and lasting for 1–3 days. The most common reactogenicity was pain at the injection site; the second most common was tiredness. Almost half (49.2%) of the physicians took acetaminophen (paracetamol) to minimize the effects of vaccine reactogenicity. Multivariate logistic regression analyses showed that physicians with diabetes and hypertension (OR = 2.729 95% CI: 1.282–5.089) and asthma with other comorbidities (OR = 1.885 95% CI: 1.001–3.551) had a significantly higher risk of vaccine‐related reactogenicities than physicians without comorbidities. Further safety studies with larger cohorts are required to monitor vaccine safety and provide assurance to potential vaccine recipients.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 89%

“…One‐quarter of respondents in a general‐population Bangladeshi study used acetaminophen to minimize vaccine‐associated discomfort, 25 as did 33.3% of HCPs in an Ethiopian study. 36 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A study in Ethiopia on adverse events among health care workers who received the Oxford/AstraZeneca vaccine noted similar results to our study. (22). Several studies have also reported no serious adverse events following vaccination with AstraZeneca (25,30).…”

Section: Discussionmentioning

confidence: 97%

Assessment of adverse events following vaccination with AstraZeneca Coronavirus Disease 2019 vaccine in Greater Kampala, Uganda, March-April 2021

Komakech¹

2022

Preprint

View full text Add to dashboard Cite

Background Tracking of adverse events following vaccination is important for evaluating vaccine safety. During March 2021, Uganda began COVID-19 vaccination using the Astra-Zeneca vaccine targeting teachers, health workers, security personnel, and the elderly. We assessed adverse events following AstraZeneca vaccination in Greater Kampala, Uganda to track the safety of the vaccine. Methods We used vaccination registers to identify persons who received ≥ 1 dose of the AstraZeneca COVID-19 vaccine during March 10–April 30, 2021. Adverse events following vaccination were defined as an untoward medical occurrence after vaccination (not necessarily causally related to the vaccine). Serious adverse events were defined as any event considered life-threatening, resulting in hospitalization, persistent disability ˃28 days, death, or congenital anomaly. We extracted telephone contacts for a systematic random sample of vaccinated individuals and their next of kin where necessary. We then conducted phone interviews to collect data on demographics and details of adverse events where they occurred. We used logistic regression analysis to establish relationships between variables and our outcome of interest (developing an adverse event following vaccination). Results Among 374 subjects interviewed, mean age was 41 years; range 20–85 years; 176 (47%) were female. Of these, 235 (63%) received only one dose and 139 (37%) received two doses. In total, 516 adverse events occurred in 286 (77%) individuals, including in 255 (68%) individuals after the first dose and in 45 (32%) individuals after the second. The most common adverse events were redness/pain/itching at the injection site (34%) and headache (32%). None of the events were classified as serious. Persons aged 20–29 years (AOR 4.7; 95% CI: 2.0–10.2), 30–39 years (AOR 3.7; 95% CI: 1.8–7.4) and 40–49 years (AOR 2.8; 95% CI 1.3–5.0) were more likely to develop adverse events than those aged ≥ 50 years. Conclusion Most individuals experienced ≥ 1 adverse event. No serious adverse events were reported. Younger age (˂50 years) was associated with adverse event. We recommend use of the AstraZeneca COVID-19 vaccine in Uganda based on its safety.

show abstract

Reporting complete heart block in a patient with polyarteritis nodosa after COVID‐19 vaccination

Nasab

Athari

2022

ESC Heart Failure

View full text Add to dashboard Cite

Complete heart block (CHB) is a serious health condition, and polyarteritis nodosa (PAN) is an important autoimmune disease. In the COVID‐19 pandemy, several vaccines were developed for the COVID‐19 disease that shown several side effects, and some of these complications are still unknown. This is the first report of CHB in a patient with history of PAN after COVID‐19 vaccination. A 68‐year‐old man with a history of PAN referred to our hospital, complaining of presyncope episodes and dizziness after receiving a COVID‐19 vaccine. Physical examination, laboratory tests, and transthoracic echocardiography were normal. In his electrocardiogram, a narrow QRS complex, AV dissociation, and junctional escape rhythm were seen. Coronary angiography showed a mild coronary artery disease. The patient, suffering from PAN for years, was hypothesized due to CHB a few days after COVID‐19 vaccination. This case report suggests that COVID‐19 vaccines may interrupt the conduction system of the heart and the fact that underlying PAN may predispose to CHB following COVID‐19 vaccination. Further studies are needed to accurately assess a possible association between PAN, CHB, and COVID‐19 vaccines.

show abstract

Adverse events of Oxford/AstraZeneca's COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia

Cited by 19 publications

References 16 publications

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians

Assessment of adverse events following vaccination with AstraZeneca Coronavirus Disease 2019 vaccine in Greater Kampala, Uganda, March-April 2021

Reporting complete heart block in a patient with polyarteritis nodosa after COVID‐19 vaccination

Contact Info

Product

Resources

About